Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/publications/12883-combined-therapy-with-ibrutinib-and-bortezomib-followed-by-ibrutinib-maintenance-in-relapsed-or-refractory-mantle-cell-lymphoma-and-high-risk-features-a-phase-12-trial-of-the-european-mcl-network-sakk-3613